Clinical Trial

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Study acronym: CLEAR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2016-06-21; most recent amendment 2026-02-11.
Status change: Recruiting → Active, Not Recruiting 2019-08-21
Status change: Not Yet Recruiting → Recruiting 2016-09-28
Trial Details
NCT Number NCT02811861
Lead Sponsor Eisai Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Renal Cell Carcinoma
Enrollment 1,069 participants
Start Date 2016-10-13
Primary Completion 2020-08-28 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-23